Outlook Therapeutics (OTLK) Stock Price, Quote, News & History | Benzinga

Outlook Therapeutics Inc (OTLK) Stock Price, Quote, News & History

OTLKNASDAQ

Trade with Public

Trade with Public

$0.3151

0.02829.83%

Last update: Apr 24, 7:56 PM

$0.3115

0.02468.57%

OverviewNews Earnings Options Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

$0.29

Close

$0.32

Volume / Avg.

4.09M / 3.07M

Day Range

$0.28 - $0.32

52 Wk Range

0.16 - 3.39

Market Cap

$37.61M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

52

Short Interest

3.88%

Days to Cover

1.02

Recent Outlook Therapeutics Inc News

Outlook Therapeutics Files FDA Resolution Request After Rejection For Vision Loss Drug

Outlook Therapeutics files FDA dispute on ONS-5010 after CRL citing effectiveness concerns; meeting with agency official set for April 2026.

Vandana Singh

Outlook Therapeutics Stock Sinks After FDA Rejects Eye Drug Again

Outlook Therapeutics' stock fell to a new low due to FDA rejection of its Lytenava filing for wet AMD. Efficacy evidence remains key issue.

Vandana Singh

Stock Market Today: S&P 500, Dow Futures Gain On The First Trading Day Of 2026— Baidu, Rubico, Intelligent Bio Solutions In Focus

U.S. stock futures rose on the first trading day of the year on Friday after missing the Santa Claus rally over the truncated week. Futures of major benchmark indices were higher. The Santa Claus trading period, which began on Dec. 24 last week, did not materialize as the S&P 500 declined for the fourth straight session, despite recording gains for 2025.

Rishabh Mishra

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-55.80M

Investing Cash Flow (TTM)

-

Financing Cash Flow (TTM)

58.78M

Free Cash Flow (TTM)

-55.80M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

2.97M

Analyst Trends and Forecast

1

Dec 25

2

Jan

2

Feb

1

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.6

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$66.85M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

60.69

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-1013.68%

Earnings Yield % (FWD)

-192.91%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$0.32

Company Debt

Total Debt

$36.66M

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$8.68M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$0.29

Close

$0.32

Volume / Avg.

4.09M / 3.07M

Day Range

$0.28 - $0.32

52 Wk Range

0.16 - 3.39

Market Cap

$37.61M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

52

Short Interest

3.88%

Days to Cover

1.02

About

Sector

Health Care

Industry

Biotechnology

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an oph...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Outlook Therapeutics (OTLK) stock?

A

You can purchase shares of Outlook Therapeutics (NASDAQ:OTLK) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Outlook Therapeutics (OTLK) competitors?

A

There are no as such competitors for Outlook Therapeutics.

Q

What is the forecast, or price target, for Outlook Therapeutics (OTLK) stock?

A

Outlook Therapeutics has a consensus price target of $3.44.

Q

What is the current price for Outlook Therapeutics (OTLK)?

A

The stock price for Outlook Therapeutics (NASDAQ: OTLK) is $0.3115 last updated April 24, 2026 at 7:56 PM EDT.

Q

Does Outlook Therapeutics (OTLK) pay a dividend?

A

There are no upcoming dividends for Outlook Therapeutics.

Q

When is Outlook Therapeutics (NASDAQ:OTLK) reporting earnings?

A

Outlook Therapeutics does not have any upcoming earnings scheduled.

Q

Is Outlook Therapeutics (OTLK) going to split?

A

There is no upcoming split for Outlook Therapeutics.

Q

What sector and industry does Outlook Therapeutics (OTLK) operate in?

A

Outlook Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.